You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses

 

Online download statistics by month:

Online download statistics by month: July 2020 to September 2025

AbstractFullPdf
Jul 202018518574
Aug 202015715879
Sep 2020616143
Oct 2020484829
Nov 2020373721
Dec 2020373725
Jan 2021626244
Feb 2021242413
Mar 2021393923
Apr 2021292916
May 2021303026
Jun 2021343423
Jul 2021262621
Aug 2021242423
Sep 2021181825
Oct 2021363643
Nov 2021434335
Dec 2021333320
Jan 2022565816
Feb 2022434320
Mar 2022525424
Apr 2022313218
May 2022495530
Jun 2022505330
Jul 2022353517
Aug 2022343721
Sep 2022323231
Oct 2022454830
Nov 2022282825
Dec 2022313215
Jan 2023343412
Feb 2023717113
Mar 2023303129
Apr 2023202015
May 2023222316
Jun 202314148
Jul 2023202011
Aug 2023303019
Sep 2023282816
Oct 202326266
Nov 202322229
Dec 2023363614
Jan 2024222317
Feb 2024252519
Mar 2024242452
Apr 2024272725
May 2024292919
Jun 2024222319
Jul 2024363514
Aug 2024171736
Sep 2024272730
Oct 2024353528
Nov 2024394119
Dec 2024242426
Jan 2025343526
Feb 2025292912
Mar 2025373732
Apr 2025454520
May 2025424244
Jun 202518186
Jul 2025110
Sep 2025220
Total229723251472